Pten Gene Mutations Drive Brain Overgrowth via Cell Overproduction

Researchers at the Institute of Science and Technology Austria revealed on Nov. 20, 2026, that losing the Pten gene in individual brain progenitor cells causes them to produce excess neurons and astrocytes, according to a study in Science Advances.

The brain organ usually maintains a remarkably consistent size across populations through precise cellular control. Rare genetic mutations disrupt this balance, leading to medical conditions characterized by abnormal brain enlargement.

The term megalencephaly describes an unusually large brain, which functions as a statistical measurement rather than a direct indicator of disease. Mutations affecting the Pten gene, which normally acts as a molecular brake on cell division, frequently link to this brain overgrowth and a heightened tumor risk.

People carrying these specific genetic changes also face higher probabilities of autism, intellectual disabilities, and epilepsy. These overlapping conditions are formally grouped under the designation PTEN Hamartoma Tumor Syndrome.

Earlier laboratory models showed that deleting Pten across an entire embryonic organism proves fatal. When scientists selectively disabled the gene strictly within the brain or cerebral cortex, mice developed megalencephaly but survived only briefly after birth. Despite those observations, researchers lacked concrete data regarding how the mutation impacts individual stem cells and their ultimate cellular output.

Cellular Family Trees Reveal Growth

To track cellular changes, the research team utilized mosaic analysis with double markers technology to switch off Pten in a tiny fraction of radial glial cells. These specialized progenitor cells reside in the cerebral cortex, multiplying first to generate neurons before later producing supportive glial cells. Labeling the modified cells with fluorescent markers allowed scientists to construct a detailed cellular family tree throughout development.

The lineage tracing demonstrated that individual radial glial cells lacking Pten produce approximately 25 percent more neurons than normal developmental pathways allow. Those mutant progenitors also produce substantially larger quantities of astrocytes, which are specialized supporting cells found throughout the central nervous system. Both the resulting neurons and astrocytes display abnormal enlargement, pointing directly to cellular overproduction as a primary driver of megalencephaly.

“People with mutations in PTEN often have megalencephaly and an increased risk of developing tumors,” said Osvaldo Miranda Romero, first author of the study and a postdoctoral researcher in the Hippenmeyer group at the Institute of Science and Technology Austria.

“They are also more likely to be on the autism spectrum, have intellectual disabilities, or experience epilepsy,” Romero said.

Signaling Pathways Shift Route

Radial glial cells rely on specific chemical instructions to determine their developmental fate, traditionally depending on the EGFR signaling pathway to manufacture astrocytes. When investigators selectively deactivated both Pten and Egfr simultaneously in radial glial cells, the cells bypassed their normal communication route entirely. Signaling activity instead shifted heavily toward the MAPK pathway in the Pten mutant cells.

“The transition from radial glial cells to astrocytes is particularly exciting,” said Romero.

“Under normal conditions, EGFR is an important driver of glial-cell formation, whereas MAPK can serve as a kind of alternative route under exceptional circumstances,” Romero said.

Patients who carry PTEN mutations frequently develop gliomas, which represent brain tumors composed of astrocytes and other glial cells. Standard clinical treatment often involves EGFR inhibitors, though some patients eventually build resistance to those pharmaceutical therapies. The discovery of an alternative MAPK signaling route highlights a promising biological target for future therapeutic research.

“Our findings suggest that the MAPK signaling pathway could be investigated as a potential therapeutic target in such cases in the future,” Romero said.

Common Inquiries About Brain Development

What causes megalencephaly in patients with PTEN mutations?

Megalencephaly stems from the loss of the Pten gene, which acts as a molecular brake on cell division in radial glial progenitor cells. Without this brake, individual progenitor cells in the cerebral cortex produce about 25 percent more neurons and a drastic excess of astrocytes, while also generating physically larger cells.

How do researchers track the growth of mutated brain cells?

Scientists use mosaic analysis with double markers technology to selectively deactivate the Pten gene in a tiny fraction of radial glial cells. They tag these affected cells with fluorescent markers to follow their lineage and measure cellular output throughout development.

Researchers at the Institute of Science and Technology Austria pursue their work within an international research institute established in 2009. Organized on the model of the Weizmann Institute of Science, the institution encourages scientists to investigate interdisciplinary themes without restrictions from government or economic interests. The organization has expanded to include 84 research groups spanning the life, formal, and physical sciences.

Why do some brain tumor patients develop drug resistance?

Patients with PTEN mutations who develop glial tumors are often treated with EGFR inhibitors, but some tumors evade the therapy. The recent study shows that Pten mutants can uncouple from EGFR signaling and switch their communication lines to the MAPK pathway.